Bronchogen vs Epithalon
Comparison of Bronchogen (Low evidence) and Epithalon (Low evidence).
Last updated: February 12, 2026
Bronchogen
Epithalon
Overview
Bronchogen and Epithalon are both studied in the peptide research space.
Bronchogen: A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support.
Epithalon: A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to activate telomerase and extend lifespan.
Evidence Comparison
| Aspect | Bronchogen | Epithalon |
|---|---|---|
| Evidence Level | Low | Low |
| Human evidence entries | 0 | 5 |
| Preclinical evidence entries | 8 | 15 |
| Sources in dossier | 12 | 28 |
These tables reproduce dossier inventory fields. Reports are not necessarily independent studies; see Cochrane Handbook, Chapter 5 for interpretation.
Key Differences
| Aspect | Bronchogen | Epithalon |
|---|---|---|
| Category | Other | Longevity |
| Evidence Strength | Low | Low |
| Sources in dossier | 12 | 28 |
| Human evidence entries | 0 | 5 |
Summary
- Bronchogen: Recorded Low dossier grade; 12 source entries, including 0 recorded human evidence entries
- Epithalon: Low evidence with 28 total sources (5 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.